<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00838838</url>
  </required_header>
  <id_info>
    <org_study_id>13900</org_study_id>
    <secondary_id>NE0501</secondary_id>
    <nct_id>NCT00838838</nct_id>
  </id_info>
  <brief_title>Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis</brief_title>
  <official_title>NebidoÂ® Therapy in Hypogonadal Male Patients With Osteoporosis Associated With Paraplegia Compared With Conventional Osteoporosis - Prophylaxis / Therapy in Hypogonadal and Eugonadal Patients With Osteoporosis Associated With Paraplegia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Both conditions hypogonadism and immobilisation (paraplegia) may contribute or lead to
      decreased bone mineral density resp osteoporosis. In this study bone mineral density is
      assessed in hypogonadal paraplegic patients, who are on standard prophylactic therapy for
      osteoporosis and and on a standard physiotherapy exercise program one group receiving Nebido
      for testosterone replacement (TRT). The additional effect of TRT on bone mineral density /
      osteoporosis is assessed (CT scan lumbar spine).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bone mineral density (CT lumbar spine)</measure>
    <time_frame>12 weeks after 4th injection</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">26</enrollment>
  <condition>Hypogonadism</condition>
  <condition>Paraplegia</condition>
  <condition>Bone Density</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Undeconate (Nebido-R, BAY86-5037)</intervention_name>
    <description>Male patients &gt; 18yrs in medical practices fulfilling all criteria for documentation.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Male patients &gt; 18yrs in medical practices fulfilling all criteria for documentation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients &gt; 18yrs

          -  Osteoporosis prophylaxis/therapy with

               -  vitamin D 800 - 1200 mg per day,

               -  calcium 800 - 1000 mg per day,

               -  Fosamax 70 once a week.

          -  Standardised physiotherapy exercise programme.

          -  No proliferative bone disease.

          -  No history of calcium oxalate stones.

          -  No use of aromatase inhibitors.

          -  No use of 5-alpha reductase inhibitors.

        Nebido group:

          -  No contraindications to use of Nebido (known prostate or breast carcinoma or suspicion
             thereof, no past or present history of liver tumours);

          -  No known hypersensitivity to testosterone or excipients of Nebido

        Exclusion Criteria:

          -  Androgen dependent carcinoma of the prostate or male mammary gland, past or present
             history of liver tumours, hypersensitivity towards the active pharmaceutical
             ingredient or other ingredients.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product</description>
  </link>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2009</study_first_submitted>
  <study_first_submitted_qc>February 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2009</study_first_posted>
  <last_update_submitted>April 13, 2010</last_update_submitted>
  <last_update_submitted_qc>April 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Director</name_title>
    <organization>Bayer Schering Pharma AG</organization>
  </responsible_party>
  <keyword>Testosterone replacement therapy</keyword>
  <keyword>Hypogonadism</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Immobilisation</keyword>
  <keyword>Paraplegia</keyword>
  <keyword>Testosterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Paraplegia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

